CONTROL

InventHelp Inventor Develops New Quality Control Systems App (LBT 402)

Retrieved on: 
星期一, 十一月 21, 2022
GMP, Multimedia, Good, Sale, CONTROL, Online shopping

PITTSBURGH, Nov. 21, 2022 /PRNewswire/ --"I thought there should be a scanning system and companion app to accurately manage a company's inventory information," said an inventor, from Audubon, Pa., "so I invented the QUALITY CONTROL SYSTEMS APP.

Key Points: 
  • PITTSBURGH, Nov. 21, 2022 /PRNewswire/ --"I thought there should be a scanning system and companion app to accurately manage a company's inventory information," said an inventor, from Audubon, Pa., "so I invented the QUALITY CONTROL SYSTEMS APP.
  • My design would help to maintain the highest possible quality standards for finished goods and operations."
  • The patent-pending invention provides an improved system for meeting Good Manufacturing Practices (GMP) requirements.
  • In doing so, it can be used for a variety of industries such as large retail and large food service operations with substantial inventory.

Natural Environmental Solutions, Inc. Not Only Offers a Product to Eradicate Zebra Mussels, But It Is Also Releasing Two More Multi-Patent Pending Products, "Stop Blue Green Algae Bloom" and "No Rodent Rocks"

Retrieved on: 
星期四, 十一月 10, 2022
Fahrenheit, Ultraviolet, Nervous system, Oxygen, CONTROL, Patent, Recreational vehicle, Aquaculture

Compacting those six essential oils into rocks using a patent pending process that infuses over 30% essential oils in one pound of selected stones and essential oil product.

Key Points: 
  • Compacting those six essential oils into rocks using a patent pending process that infuses over 30% essential oils in one pound of selected stones and essential oil product.
  • "Stop Blue Green Algae Blooms" is a product that demonstrates the blooms falling back from the surface layer, where it goes to get oxygen needed for blooming activity.
  • "Stop Blue Green Algae Blooms" sells for the price of $25.00 for 100 square feet, just by sprinkling on the active blooms.
  • For more information; "No Rodent Rocks" ( https://NoRodentRocks.com ) and "Stop Blue Green Algae Blooms" ( https://BlueGreenAlgaeControl.com ) are available December 2022.

InventHelp Inventor Develops Substance Abuse Control Device (PND-5045)

Retrieved on: 
星期五, 九月 30, 2022
CONTROL, Multimedia, Ninth Street, Sale, Substance abuse, Pharmaceutical industry

PITTSBURGH, Sept. 30, 2022 /PRNewswire/ -- "I thought there could be a device to help augment a more traditional substance abuse recovery program," said an inventor, from Darby, Pa., "so I invented the SUBSTANCE ABUSE CONTROL DEVICE.

Key Points: 
  • PITTSBURGH, Sept. 30, 2022 /PRNewswire/ -- "I thought there could be a device to help augment a more traditional substance abuse recovery program," said an inventor, from Darby, Pa., "so I invented the SUBSTANCE ABUSE CONTROL DEVICE.
  • The invention helps to prevent relapse for those recovering from substance abuse.
  • In doing so, it offers an effective way to alert the user if entering a bar or related establishment.
  • Additionally, the invention features a discreet design that is easy to wear and use so it is ideal for individuals recovering from substance abuse.

InventHelp Inventor Develops Control Switch Cover for Vehicles (JTK-134)

Retrieved on: 
星期二, 九月 13, 2022
SWITCH, CONTROL, Weather, Safety, PETS, Jackson, Ninth Street, Sale

PITTSBURGH, Sept. 13, 2022 /PRNewswire/ -- "I wanted to create a way to prevent a family pet from accidentally pressing the power control switches at the inner door panel while riding in the car," said an inventor, from Tylertown, Miss., "so I invented the CONTROL SWITCH COVER.

Key Points: 
  • PITTSBURGH, Sept. 13, 2022 /PRNewswire/ -- "I wanted to create a way to prevent a family pet from accidentally pressing the power control switches at the inner door panel while riding in the car," said an inventor, from Tylertown, Miss., "so I invented the CONTROL SWITCH COVER.
  • My design would alleviate concern over the pet opening the window or activating the door locks."
  • The invention provides an effective way to shield the control switches at a vehicle's inner door panel.
  • 20-JTK-134, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

CF Acquisition Corp. VI Reminds Stockholders to Vote in Favor of its Business Combination with Rumble, Inc.

Retrieved on: 
星期二, 九月 6, 2022
Date, COVID-19, Prospectus, Securities Act of 1933, Proxy, Risk, Culture, Gulf of Mexico, Federal Reserve Bank of New York, U.S. Securities and Exchange Commission, NEW, Telephone, Registration statement, Federal Reserve Bank, Vii, Longboat Key, Florida, Sale, 100,000, SEC, FORM, Securities Exchange Act of 1934, Internet, Proxy statement, PIPE, Multimedia, Special, Probability, Business, Growth, Acquisition, CF, High, SPAC, XV, Register, Person, CONTROL, Business architecture, Form, Failure, Forward-looking statement, Online gambling, Holding company, Internet service provider, Security (finance), Nasdaq, Rumble, Eastern Time Zone

NEW YORK, Sept. 6, 2022 /PRNewswire/ -- CF Acquisition Corp. VI (Nasdaq: CFVI) ("CFVI"), a publicly traded special purpose acquisition company sponsored by Cantor Fitzgerald, reminds its stockholders to vote in favor of its previously announced business combination (the "Business Combination") with Rumble, Inc. ("Rumble"), the fast-growing neutral video platform.

Key Points: 
  • Stockholders who owned common stock of CFVI as of the close of business on July 25, 2022 (the "Record Date"), may vote their shares.
  • Every stockholder's vote is important, regardless of the number of shares a stockholder held as of the Record Date.
  • To vote online, you will need your voting control number, which you can find on your Voting Instruction Form.
  • Vote by Telephone:Follow the instructions provided by your broker, bank or other nominee on the Voting Instruction Form mailed (or e-mailed) to you.

How Customer Support Increases Customer Loyalty in Times of Crisis

Retrieved on: 
星期三, 八月 31, 2022
VP, ISO, OTRS, Documentation, Federal, Solution, Information technology, Toyota, BSI, CONTROL, Customer service, Frankfurt Stock Exchange, Investment, Leadership, Learning, Communication, Max Planck Society, Lufthansa, Automation, Security, TUI Cruises, Retail, Public relations, Sales, Airbus, Porsche

RALEIGH, N.C., Aug. 31, 2022 /PRNewswire-PRWeb/ -- Rising inflation is leading to more frugality in many parts of the world - this can be seen in both consumer markets and business-to-business (B2B): The current crises are causing many companies to view planned investments with more caution and to delay them. When new business becomes difficult in such times, good customer service can not only ensure stable and good customer relationships, but also offer additional cross-selling and up-selling business.

Key Points: 
  • OTRS Group surveyed 500 international customer service leaders and shows how important customer service is for customer loyalty and satisfaction, and how important it is to work together with other departments in the company.
  • When new business becomes difficult in such times, good customer service can not only ensure stable and good customer relationships, but also offer additional cross-selling and up-selling business.
  • The first part shows how important customer service is for customer loyalty and satisfaction, and how important it is to work together with other departments in the company.
  • To be able to support customers effectively, you need a customer service team that can not only offer solutions, but ideally implement these directly.

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

Retrieved on: 
星期一, 八月 29, 2022
Ichthyosis, Security (finance), X-linked recessive inheritance, Safety, Securities Exchange Act of 1934, NYSE, Securities Act of 1933, Incidence, Lumber, CI, CONTROL, CMC, Isotretinoin, Quality of life, Chemistry, U.S. Securities and Exchange Commission, GLOBE, Journal of the European Academy of Dermatology and Venereology, Company, FDA, 2021 Essex County Council election, Genta (company), Congress, Private Securities Litigation Reform Act, Intellectual property, Industry, Annual report, Patient, Nature, Pharmaceutical industry, Dermatology

BASKING RIDGE, NJ, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that seven abstracts detailing positive clinical data from the completed Phase 2b CONTROL study of TMB-001 were accepted for e-poster presentation at the 31st European Academy of Dermatology and Venerology (EADV) Congress, which will be held in Milan, Italy and virtually from September 7-10, 2022. TMB-001 is a topical isotretinoin formulation in development based on the Company’s patented IPEG™ delivery system for the treatment of moderate to severe forms of congenital ichthyosis (CI), a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin. In May 2022, the FDA designated TMB-001 as a breakthrough therapy for the treatment of CI.

Key Points: 
  • In May 2022, the FDA designated TMB-001 as a breakthrough therapy for the treatment of CI.
  • The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles.
  • The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI) and other sclerotic skin diseases.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

Retrieved on: 
星期五, 八月 26, 2022
Patient, Security (finance), XLRI, X-linked recessive inheritance, Safety, IGA, NYSE, Securities Exchange Act of 1934, Pharmacokinetics, Securities Act of 1933, PP, American Academy, Professor, ITT, Lumber, Mark (given name), Drug Quality and Security Act, CI, CONTROL, CMC, Isotretinoin, Chemistry, U.S. Securities and Exchange Commission, Journal, GLOBE, Journal of the American Academy of Dermatology, Moisturizer, Company, Population, Stanford University, ASCEND, Genta (company), Clinical trial, Private Securities Litigation Reform Act, Ichthyosis, Intellectual property, Industry, Annual report, Nature, Pharmaceutical industry, Diesel fuel, Dermatology

BASKING RIDGE, NJ, Aug. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced that results from the previously completed Phase 2b CONTROL study that evaluated TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, in moderate to severe congenital ichthyosis (CI) are published in the Journal of the American Academy of Dermatology.

Key Points: 
  • We want to thank all prior and current investigators and patients who have helped us get to this point.
  • These results support ongoing TMB-001 efficacy and safety investigation as a promising alternative to oral retinoids for patients with CI.
  • Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Professional Golfer Aza Muñoz Returns to LPGA Tour with New Solution for Treating Her Hypothyroidism

Retrieved on: 
星期三, 八月 24, 2022
Sports, General Sports, Alternative Medicine, Managed Care, Other Health, Health, Seniors, Pharmaceutical, Golf, Hispanic, Consumer, Muscle weakness, Insurance, Rash, Thyroiditis, Myocardial infarction, Breathe Me, Absorption, Irritability, Glycerol, Risk, Hypothyroidism, Levothyroxine, Patient, Diabetes, Cardiovascular disease, Menstruation, Obesity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Appetite, Food, Hashimoto's thyroiditis, Headache, Insomnia, Heat intolerance, Tremor, Weight gain, FDA, Weight loss, THE, Social media, Partnership, Tablet, Spasm, Diarrhea, Stiff-person syndrome, Lists of diseases, Thyroid hormones, Pharmacy, Nervous, Diet, Multimedia, Water, Plasma protein binding, Â, Aza, LPGA, Health, Atrial fibrillation, IBSA, Hyperthyroidism, LPGA Tour Championship, Golf, McMillan, Arrhythmia, Diagnosis, CONTROL, Excipient, Common, Lethargy, Adrenal insufficiency, Public relations, Pharmaceutical industry, Meat

Professional golfer Azahara (Aza) Muoz will return to the LPGA Tour this fall as a new mom and as the new spokesperson for Tirosint-SOL (levothyroxine sodium) solution .

Key Points: 
  • Professional golfer Azahara (Aza) Muoz will return to the LPGA Tour this fall as a new mom and as the new spokesperson for Tirosint-SOL (levothyroxine sodium) solution .
  • My body ached, and practicing golf was so tough because I was always tired, said Muoz.
  • She tried to treat her condition using conventional thyroid medicine, but she still struggled with the symptoms of hypothyroidism.
  • We wish Aza the best of luck and health as she returns to the Tour!

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results

Retrieved on: 
星期四, 八月 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intellectual property, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Ichthyosis, Industry, NYSE, GLOBE, American Academy, Securities Exchange Act of 1934, Clinical trial, Isotretinoin, Toxicity, Breakthrough therapy, XRI, Security (finance), X-linked ichthyosis, Annual report, Patient, Review, Company, Journal of the American Academy of Dermatology, Skin, ASCEND, Nature, CONTROL, Â, Genta (company), Chemistry, Securities Act of 1933, Private Securities Litigation Reform Act, Fast Track, CMC, Food, Program, Pharmaceutical industry, Lumber

BASKING RIDGE, NJ, Aug. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter of 2022, ended June 30, 2022.

Key Points: 
  • BASKING RIDGE, NJ, Aug. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter of 2022, ended June 30, 2022.
  • John Koconis, Chairman and Chief Executive Officer of Timber, commented, During the second quarter, Timber achieved several significant milestones for our lead asset, TMB-001.
  • Timber recognized no revenue in the second quarter of 2022 compared to revenue of $388,819 for the second quarter of 2021.
  • First the first six months of 2022, Timber recognized revenue of $83,177 in the 2022 period and $429,553 in the 2021 period.